Results 11 to 20 of about 52,189 (266)
Antigen-specific cytokine profiles for pulmonary Mycobacterium avium complex disease stage diagnosis
Frontiers in Immunology, 2023 IntroductionControlling pulmonary Mycobacterium avium complex (MAC) disease is difficult because there is no way to know the clinical stage accurately. There have been few attempts to use cell-mediated immunity for diagnosing the stage.
Yoshiro Yamashita +16 more
doaj +1 more source
Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
Translational Oncology, 2023 Previous studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar ...
Shang-Ju Wu +3 more
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2013 BACKGROUND AND OBJECTIVES: The role of bone marrow-mesenchymal stem cells (BM-MSC) in leukae-mic cell control is controversial. The purpose of this work was to evaluate BM-MSC role regarding the viability, proliferation and immunophenotype of normal B ...
Viviana M Rodríguez-Pardo +7 more
doaj +1 more source
BLDE University Journal of Health Sciences, 2022 BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease as it affects multiple lineages of hematopoietic cells. AIMS AND OBJECTIVES: This study aims to (1) evaluate the immunophenotypic findings of AML patients, (2) correlate the ...
Mekhala Rao +3 more
doaj +1 more source
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor [PDF]
Journal of Immunotherapy, 2009 T cells can be engineered to express the genes of chimeric antigen receptors (CARs) that recognize tumor-associated antigens. We constructed and compared 2 CARs that contained a single chain variable region moiety that recognized CD19. One CAR contained the signaling moiety of the 4-1BB molecule and the other did not.
James N, Kochenderfer +7 more
openaire +2 more sources
Biomedicines, 2023 Background: Therapeutic options for CD19+ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed.
Audrey Grain +6 more
doaj +1 more source
Folia Histochemica et Cytobiologica, 2010 Numerous experimental data indicate that B-CLL development and progression are influenced by antigenic pressure. It can not be excluded that these antigens may originate from bacteria and viruses.
Barbara Marzec-Kotarska +4 more
doaj +1 more source
Unifying heterogeneous expression data to predict targets for CAR-T cell therapy
OncoImmunology, 2021 Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression ...
Patrick Schreiner +4 more
doaj +1 more source
Distinct and shared B cell responses of tuberculosis patients and their household contacts
PLoS ONE, 2022 This study was aimed at identifying the B cell responses which could distinguish between ‘latent tuberculosis infection (LTBI)’ and active TB disease. Study subjects were smear-positive TB patients (n = 54) and their disease-free household contacts (HHCs,
Komal Singh +5 more
doaj
Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides
Journal of Immunology Research, 2015 We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study.
Serkan Yazıcı +9 more
doaj +1 more source